Main results of cost-effectiveness analysis of Model B
| First-line treatment analysis . | Ibrutinib . | VenO . | Incremental . | ICER . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cost, € . | QALY . | Life y . | Cost, € . | QALY . | Life y . | Cost, € . | QALY . | Life y . | (€/QALY) . | |
| Base case | 392 743 | 5.62 | 9.13 | 236 576 | 4.95 | 7.57 | 156 167 | 0.67 | 1.56 | 232 473 |
| Same OS curve | 392 743 | 5.62 | 9.13 | 236 576 | 5.73 | 7.57 | 156 167 | −0.11 | 0 | −1 419 700 |
| Ibrutinib until progression | 801 587 | 5.06 | 9.13 | 253 346 | 4.94 | 7.57 | 548 241 | 0.12 | 1.56 | 4 410 969 |
| Only first line | 307 442 | 6.87 | 11.12 | 109 187 | 6.60 | 10.11 | 198 255 | 0.27 | 1.01 | 739 012 |
| First-line treatment analysis . | Ibrutinib . | VenO . | Incremental . | ICER . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cost, € . | QALY . | Life y . | Cost, € . | QALY . | Life y . | Cost, € . | QALY . | Life y . | (€/QALY) . | |
| Base case | 392 743 | 5.62 | 9.13 | 236 576 | 4.95 | 7.57 | 156 167 | 0.67 | 1.56 | 232 473 |
| Same OS curve | 392 743 | 5.62 | 9.13 | 236 576 | 5.73 | 7.57 | 156 167 | −0.11 | 0 | −1 419 700 |
| Ibrutinib until progression | 801 587 | 5.06 | 9.13 | 253 346 | 4.94 | 7.57 | 548 241 | 0.12 | 1.56 | 4 410 969 |
| Only first line | 307 442 | 6.87 | 11.12 | 109 187 | 6.60 | 10.11 | 198 255 | 0.27 | 1.01 | 739 012 |